ORN Fall 2023 - Operationalizing a Definition of Precipitated Withdrawal and the Absorption, Distribution, Metabolism, and Elimination of Illicitly Manufactured Fentanyl-Recording

Video Transcription

Video Summary

In this webinar, Dr. Kelly Dunn discusses fentanyl and its pharmacologic properties, as well as withdrawal mitigation. She explains that fentanyl is an opioid that was designed to be highly lipophilic, meaning it is fat soluble and can rapidly cross the blood-brain barrier to produce rapid onset effects. Fentanyl is highly potent at mu opioid receptors, which are responsible for producing typical opioid effects such as analgesia and euphoria. It is commonly used in hospital settings for analgesia and anesthesia. Illicitly manufactured fentanyl has become a major concern due to its role in the opioid crisis. It is relatively easy and cheaper to produce compared to heroin, and can be easily hidden in other substances. Illicitly manufactured fentanyl has a different pharmacokinetic profile compared to medicinal fentanyl, with potential for deeper physical dependence and unique withdrawal symptoms. Dr. Dunn discusses a study that compared withdrawal experiences between individuals exposed to illicitly manufactured fentanyl and those exposed to other opioids. The results showed significantly higher withdrawal severity in the fentanyl-exposed group. She also presents an operational definition for precipitated withdrawal in individuals transitioning from fentanyl to buprenorphine, based on changes in withdrawal ratings within one hour of administration. Dr. Dunn concludes by emphasizing the need for more research in this area to better understand and address the effects of fentanyl. Credits: Dr. Kelly Dunn, Ph.D., the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, Cure Addiction Now, the National Institute on Drug Abuse, the Journal of Addiction Medicine. Contact information: Dr. Kelly Dunn's email is provided for further inquiries.

Keywords

webinar

Dr. Kelly Dunn

fentanyl

pharmacologic properties

withdrawal mitigation

opioid crisis

illicitly manufactured fentanyl

pharmacokinetic profile

withdrawal severity